CSU Animal Cancer Center Clinical Trial

Patient Disease:
Mast cell tumor.

Study Name:
Pharmacokinetics of vinblastine in dogs with mast cell tumors.

Purpose of the Study:
Mast cell tumor is a common skin tumor of dogs. Current treatment options available for mast cell tumor include various combinations of surgery, chemotherapy drugs such as vinblastine or lomustine, radiation therapy, and the new oral mast cell tumor drug Palladia^® (toceranib).

Vinblastine is an intravenous chemotherapy agent that is commonly used in the treatment of mast cell tumors. The aim of this study is to determine the concentration of the drug in the blood at different times following intravenous administration. This information has not yet been established in dogs and may vary among individuals. Information gained from this study will help us determine the pharmacokinetics of vinblastine and may help us tailor vinblastine doses for individual patients in the future.

Patient Entry Criteria:
Dogs with confirmed mast cell tumor that are clinically well are eligible for this study. Dogs must undergo some diagnostic testing prior to starting the study to ensure that they are eligible, including bloodwork (complete blood count and chemistry profile). They must have acceptable blood cell counts and be healthy enough to undergo chemotherapy.

Owner Responsibilities:
The owner is responsible for scheduling appointments with the oncology clinical trials coordinator and keeping those appointments as required by study protocol.  The owner is responsible for the costs of diagnosis and staging of the mast cell tumor prior to entering the study.

Financial Incentives:
Clients participating in this study will be given special financial considerations. Specifically, the study will pay for the costs associated with the study, hospitalization as well as cost and administration of the vinblastine. Additionally a $100 credit will be applied the client’s hospital account.

If you have further questions about any of our clinical trials, please complete an online consult request form below or call or Oncology Clinical Coordinator at (970) 297-4068.